The Non-Profit Standard for Rare Disease Intelligence.

---

About the Consortium

Regal Intel serves as the non-profit dedicated to accelerating the search for cures for rare and complex diseases. We connect hospitals that treat patients with researchers developing new medicines. Utilizing a secure Sovereign Intelligence model, we enable hospitals to engage in this critical work without ever sending private medical records beyond their walls. This method safeguards privacy while assisting pharmaceutical partners in creating safer, faster clinical trials—often by employing weighted data to minimize the necessity for placebo groups. By linking these two spheres, Regal Intel ensures that new therapies can be approved more swiftly while maintaining strict protection of every patient's privacy.

Bridging Care and Cures through Sovereign Intelligence.

Regal Intel is a non-profit research consortium dedicated to a singular, urgent goal: shortening the journey from symptom to cure for patients with rare and complex conditions. We function as the neutral bridge between health systems that cater to these patients and life sciences innovators, including Regal Technology Partners, who are working to find cures. Regal Intel was established to address this issue by transforming the medical research model.

Our Purpose: Connecting a Fragmented Ecosystem

For patients with rare diseases, the "Diagnostic Odyssey" can extend for years. The clues necessary to diagnose these conditions—and the data essential for developing new therapies—are frequently scattered across thousands of disconnected hospitals. Traditionally, connecting these dots necessitated transferring patient data into central databases, which created privacy risks and legal obstacles.

Our Approach: Sovereign Intelligence

We specialize in deploying Sovereign Intelligence. Rather than requesting hospitals to disclose their sensitive records, we bring our research algorithms directly to the data source.

For Health Systems: We implement advanced diagnostic tools within your secure firewall. These tools analyze local records to identify undiagnosed risks and complex conditions, enabling you to enhance care while keeping your Patient Health Information (PHI) under your control.

For Biotech & Pharma: We aggregate insights—not raw data—from this global network. We provide regulatory-grade Real-World Evidence (RWE) and "Synthetic Control Arms" that expedite clinical trials, reducing the cost and time needed to bring new orphan drugs to market.

Our Expertise

We extend beyond standard analytics. Our consortium is built upon deep expertise in regulatory science and data scarcity. We specialize in validating digital biomarkers for conditions that are "statistically invisible" to traditional methods, ensuring that even the rarest phenotypes produce robust, FDA-aligned evidence.

Why We Are Different

As a non-profit, we are not motivated by data monetization, but by the necessity for answers. We offer a trusted environment where hospitals can benchmark their care globally while remaining sovereign locally, and where pharmaceutical partners can access the high-fidelity evidence they need to save lives.

Global Answers. Local Privacy. One Consortium.